Anthem Biosciences releases unaudited Q2 FY2026 results via investor presentation

What Anthem Biosciences announced

Anthem Biosciences Ltd filed an Investor Presentation under Regulation 30 (LODR) on 21 July 2026. The presentation provides the company’s unaudited consolidated financial results for the quarter ended 30 June 2026. The filing was made on the BSE platform and is identified by the BSE code 544449.

Presentation details

The investor presentation is a standard quarterly disclosure required by the Listing Obligations and Disclosure Requirements (LODR) framework. It contains the company’s financial performance for the second quarter of fiscal year 2026, including revenue, profit, and segment‑wise analysis, though the exact figures are not reproduced in the filing summary. The results are unaudited, meaning they have not yet been examined by an independent auditor and are subject to revision.

Regulatory filing information

• Filing date: 21 July 2026, 11:22:50 UTC
• Regulation invoked: Regulation 30 (LODR)
• Document type: Investor Presentation (PDF)
• Source: BSE (link to PDF provided in the filing)
• Exchange/Ticker: BSE – 544449 (no NSE ticker listed)

Key facts at a glance

Why this matters for investors

The filing informs shareholders that the company has generated its quarterly financial data and is making it publicly available, albeit in an unaudited form. Investors can review the performance trends, compare them with prior quarters, and assess operational health. Because the numbers are unaudited, they should be treated as provisional until the audited statements are released, typically in the subsequent quarter’s annual filing.

Conclusion

Anthem Biosciences has complied with its LODR obligations by releasing an investor presentation on its Q2 FY2026 unaudited results on 21 July 2026. The detailed financial figures remain within the PDF document, and the results will later be audited and incorporated into the company’s formal quarterly report.